168 related articles for article (PubMed ID: 16298830)
1. Highly conserved antigenic structure of the factor VIII C2 domain in some mammals.
Ori J; Tanaka I; Kubota Y; Shima M; Matsumoto T; Yoshida K; Sakurai Y; Yoshioka A
Int J Hematol; 2005 Nov; 82(4):351-6. PubMed ID: 16298830
[TBL] [Abstract][Full Text] [Related]
2. Anti-factor VIII inhibitor alloantibodies recognizing the A2 domain in the human factor VIII heavy chain poorly bind to porcine factor VIII.
Sawamoto Y; Shima M; Tanaka I; Nakai H; Kamisue S; Scandella D; Yoshioka A
Int J Hematol; 1997 Feb; 65(2):151-8. PubMed ID: 9071819
[TBL] [Abstract][Full Text] [Related]
3. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes.
Suzuki H; Shima M; Arai M; Kagawa K; Fukutake K; Kamisue S; Nakai H; Morichika S; Tanaka I; Inoue M; Gale K; Tuddenham EG; Yoshioka A
Thromb Haemost; 1997 May; 77(5):862-7. PubMed ID: 9184393
[TBL] [Abstract][Full Text] [Related]
4. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules.
Barrow RT; Healey JF; Gailani D; Scandella D; Lollar P
Blood; 2000 Jan; 95(2):564-8. PubMed ID: 10627463
[TBL] [Abstract][Full Text] [Related]
5. Hybrid human-porcine factor VIII proteins partially escape the inhibitory effects of anti-factor VIII inhibitor alloantibodies having A2 or C2 domain specificity.
Mizumachi K; Nakajima Y; Shimonishi N; Furukawa S; Ogiwara K; Takeyama M; Nogami K
Haemophilia; 2024 Jan; 30(1):140-150. PubMed ID: 38058226
[TBL] [Abstract][Full Text] [Related]
6. Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism.
Nogami K; Shima M; Nishiya K; Sakurai Y; Tanaka I; Giddings JC; Saenko EL; Yoshioka A
Thromb Haemost; 2002 Mar; 87(3):459-65. PubMed ID: 11916079
[TBL] [Abstract][Full Text] [Related]
7. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.
Shima M; Scandella D; Yoshioka A; Nakai H; Tanaka I; Kamisue S; Terada S; Fukui H
Thromb Haemost; 1993 Mar; 69(3):240-6. PubMed ID: 7682339
[TBL] [Abstract][Full Text] [Related]
8. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.
Scandella DH; Nakai H; Felch M; Mondorf W; Scharrer I; Hoyer LW; Saenko EL
Thromb Res; 2001 Mar; 101(5):377-85. PubMed ID: 11297754
[TBL] [Abstract][Full Text] [Related]
9. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
Yada K; Nogami K; Shima M
Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
[TBL] [Abstract][Full Text] [Related]
10. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.
Yada K; Nogami K; Takeyama M; Ogiwara K; Wakabayashi H; Shima M
J Thromb Haemost; 2015 Oct; 13(10):1843-53. PubMed ID: 26278069
[TBL] [Abstract][Full Text] [Related]
11. Antigenicity of putative phospholipid membrane-binding residues in factor VIII.
Barrow RT; Healey JF; Jacquemin MG; Saint-Remy JM; Lollar P
Blood; 2001 Jan; 97(1):169-74. PubMed ID: 11133757
[TBL] [Abstract][Full Text] [Related]
12. Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.
Kahle J; Orlowski A; Stichel D; Healey JF; Parker ET; Jacquemin M; Krause M; Tiede A; Schwabe D; Lollar P; Königs C
Blood; 2017 Aug; 130(6):808-816. PubMed ID: 28507083
[TBL] [Abstract][Full Text] [Related]
13. Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect.
Nogami K; Shima M; Nakai H; Tanaka I; Suzuki H; Morichika S; Shibata M; Saenko EL; Scandella D; Giddings JC; Yoshioka A
Br J Haematol; 1999 Oct; 107(1):196-203. PubMed ID: 10520041
[TBL] [Abstract][Full Text] [Related]
14. An alloantibody recognizing the FVIII A1 domain in a patient with CRM reduced haemophilia A due to deletion of a large portion of the A1 domain DNA sequence.
Shibata M; Shima M; Morichika S; McVey J; Tuddenham EG; Tanaka I; Suzuki H; Nogami K; Minamoto Y; Hato T; Saenko EL; Scandella D; Yoshioka A
Thromb Haemost; 2000 Sep; 84(3):442-8. PubMed ID: 11019969
[TBL] [Abstract][Full Text] [Related]
15. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII.
Pittman DD; Alderman EM; Tomkinson KN; Wang JH; Giles AR; Kaufman RJ
Blood; 1993 Jun; 81(11):2925-35. PubMed ID: 8499631
[TBL] [Abstract][Full Text] [Related]
16. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor.
Shima M; Nakai H; Scandella D; Tanaka I; Sawamoto Y; Kamisue S; Morichika S; Murakami T; Yoshioka A
Br J Haematol; 1995 Nov; 91(3):714-21. PubMed ID: 8555081
[TBL] [Abstract][Full Text] [Related]
17. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.
Prescott R; Nakai H; Saenko EL; Scharrer I; Nilsson IM; Humphries JE; Hurst D; Bray G; Scandella D
Blood; 1997 May; 89(10):3663-71. PubMed ID: 9160671
[TBL] [Abstract][Full Text] [Related]
18. High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.
Nguyen PC; Lewis KB; Ettinger RA; Schuman JT; Lin JC; Healey JF; Meeks SL; Lollar P; Pratt KP
Blood; 2014 Apr; 123(17):2732-9. PubMed ID: 24591205
[TBL] [Abstract][Full Text] [Related]
19. Epitope mapping of human factor VIII inhibitor antibodies by site-directed mutagenesis of a factor VIII polypeptide.
Ware J; MacDonald MJ; Lo M; de Graaf S; Fulcher CA
Blood Coagul Fibrinolysis; 1992 Dec; 3(6):703-16. PubMed ID: 1283342
[TBL] [Abstract][Full Text] [Related]
20. A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII.
Eubanks J; Baldwin WH; Markovitz R; Parker ET; Cox C; Kempton CL; Meeks SL
Blood; 2016 Apr; 127(16):2028-34. PubMed ID: 26825708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
